Activities of an intravenous formulation of itraconazole in experimental disseminated Aspergillus, Candida, and Cryptococcus infections.
Antimicrob Agents Chemother
; 44(11): 3180-3, 2000 Nov.
Article
en En
| MEDLINE
| ID: mdl-11036047
ABSTRACT
An intravenous (i.v.) formulation of itraconazole was evaluated in disseminated fungal infection models in guinea pigs. In acute disseminated Candida albicans and Aspergillus fumigatus infections, treatment at 5 mg/kg of body weight twice a day (b.i.d.) significantly prolonged survival. In these models and in animals with chronic disseminated cryptococcosis, itraconazole given i.v. at 2.5 and 5 mg/kg b.i.d. greatly reduced the proportions of organs with culture-detectable fungal burdens. The efficacy of i.v. itraconazole in these animal models justifies its further investigation for the treatment of life-threatening mycoses in humans.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Aspergilosis
/
Candidiasis
/
Itraconazol
/
Criptococosis
/
Antifúngicos
Límite:
Animals
Idioma:
En
Revista:
Antimicrob Agents Chemother
Año:
2000
Tipo del documento:
Article
País de afiliación:
Reino Unido